Adjuvant effects of combination monophosphoryl lipid A and poly I:C on antigen-specific immune responses and protective efficacy of influenza vaccines.

Abstract

Toll-like receptor (TLR) agonists improve vaccine immunogenicity and efficacy, but they are currently unlicensed as adjuvants in influenza vaccines. This study aimed to investigate whether a combination of monophosphoryl lipid A (MPL, a TLR4 agonist) and polyriboinosinic polyribocytidylic acid (poly I:C, a TLR3 agonist) can enhance the protective efficacy of an inactivated A/Puerto Rico/8/1934 (A/PR8) H1N1 influenza vaccine against homologous influenza infection and minimize illness outcomes. Results showed that combination MPL and poly I:C adjuvanted influenza vaccination increased the production of antigen-specific antibodies, decreased the levels of cytokines and cellular infiltrates at the infection sites, and induced significant memory T and B cell responses in mice. The results of this study suggest that the combination of MPL and poly I:C can be developed into a possible adjuvant for enhancing the efficacy of influenza vaccines.

• Authors: Chau Thuy Tien Le, So Yeon Ahn, Thi Len Ho, Jueun Lee, Dong-Ha Lee, Hye Suk Hwang, Sang-Moo Kang, Eun-Ju Ko
• Journal: Scientific reports (Sci Rep) Vol. 13 Issue 1 Pg. 12231 (07 28 2023) ISSN: 2045-2322 [Electronic] England
• PMID: 37507413 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2023. The Author(s).

Chemical References

• Influenza Vaccines
• Poly I-C
• monophosphoryl lipid A
• Antibodies, Viral
• Adjuvants, Immunologic
• Adjuvants, Pharmaceutic

Topics

• Animals
• Mice
• Humans
• Influenza Vaccines
• Influenza, Human
• Poly I-C (pharmacology)
• Influenza A Virus, H1N1 Subtype
• Antibodies, Viral
• Adjuvants, Immunologic (pharmacology)
• Immunity
• Adjuvants, Pharmaceutic
• Mice, Inbred BALB C